Figure 6
Decreased inflammatory cytokine production and increased insulin sensitivity in RSG-treated STAT6-deficient mice.
(a) Western blot of PKM2 in WAT of control and RSG-treated mice, (n = 5/group). (b) Serial immunohistochemical and histological stainings from adipose tissue sections of RSG-treated STAT6-deficient mice. The middle section was used for PKM2 labelling and the two adjacent sections were used for markers for the macrophage markers CD206 (M2 type) and F4/80 (M1 type) (c) Real-time PCR analysis of MCP1and IL-1β expression (d) Intraperitoneal insulin tolerance test (ipITT). Mice (n = 4–5/group) were starved overnight and injected intraperitonelly by insulin (1 U/Kg) and glucose levels were monitored for a period of one hour. Graph represents glucose levels expressed as the percentage of initial level. (e) AUC = area under the curve. All graphs represent mean ± S.E.M expressed as arbitrary units normalized to the mean of control WT mice. Results were analyzed by one-way ANOVA test, * # = p ≤ 0.05, (* WT vs. STAT6-deficient mice; #Control vs. RSG-treated mice). All runs were done in parallel with the same experimental conditions.
